Elekta AB (publ) (EKTAY) Projected to Post Quarterly Earnings on Thursday

Elekta AB (publ) (OTCMKTS:EKTAY - Get Free Report) is projected to announce its earnings results on Thursday, March 6th. Analysts expect the company to announce earnings of $0.09 per share and revenue of $444.70 million for the quarter.

Elekta AB (publ) (OTCMKTS:EKTAY - Get Free Report) last released its quarterly earnings data on Friday, February 21st. The company reported $0.08 earnings per share for the quarter, missing the consensus estimate of $0.09 by ($0.01). The firm had revenue of $416.86 million during the quarter, compared to analyst estimates of $435.89 million. Elekta AB (publ) had a net margin of 5.65% and a return on equity of 11.07%. On average, analysts expect Elekta AB (publ) to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Elekta AB (publ) Trading Up 0.2 %

EKTAY traded up $0.01 on Friday, reaching $5.43. 9,765 shares of the company's stock were exchanged, compared to its average volume of 8,953. The company has a market cap of $2.08 billion, a price-to-earnings ratio of 21.72 and a beta of 1.22. The company has a debt-to-equity ratio of 0.60, a quick ratio of 0.81 and a current ratio of 1.05. Elekta AB has a twelve month low of $5.25 and a twelve month high of $8.24. The company's 50 day moving average is $5.72 and its 200-day moving average is $6.06.

Elekta AB (publ) Cuts Dividend

The firm also recently disclosed a dividend, which will be paid on Thursday, March 27th. Stockholders of record on Friday, March 7th will be given a $0.1072 dividend. The ex-dividend date of this dividend is Friday, March 7th. Elekta AB (publ)'s payout ratio is currently 40.00%.

Remove Ads

Analyst Upgrades and Downgrades

Separately, Sanford C. Bernstein upgraded shares of Elekta AB (publ) from a "strong sell" rating to a "hold" rating in a report on Wednesday, January 29th.

Elekta AB (publ) Company Profile

Elekta AB (publ), a medical technology company, provides clinical solutions for treating cancer and brain disorders worldwide. The company offers Versa HD, a brain metastases solution; Elekta Unity for real-time MR visualization; Elekta Harmony, a linear accelerator; Elekta Infinity for treating a range of patients with simple-to-complex radiotherapy needs; Elekta Synergy, a digital accelerator for image guided radiation therapy; treatment and workflow management solutions; radiation and medical oncology; and other patient services.